Presently, the currently recruiting MiST trial (NCT03654833) includes an arm of MMe patients selected by the p16/INK4A deficiency, who will receive Abemaciclib in monotherapy as a treatment. Here, CDKN2A is linked to hyperinsulinemic hypoglycemia, familial, 4.